Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ibrutinib+obinutuzumab vs chlorambucil+obinutuzumab in treatment-naïve CLL/SLL; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Chlorambucil (chlorambucil)
• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Chronic Lymphocytic Leukemia, Small-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2019-04-16